Over the past several months, Federal Trade Commission (FTC) oversight has been unprecedently high when it comes to exit transactions. Additionally, rules are changing in real time that affect M&A transactions and licensing collaborations, especially in the life sciences industry.
Join our panel as they discuss FTC key players and their antitrust concerns when dealing with these type of transactions. Our speakers will also discuss when collaborations agreements go sideways, and potential litigation issues and avoidance.
1 CLE Credit Pending (CA, CT, FL, GA, IL, NJ, NY, PA, TX, VA).